Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
Feature|Videos|January 9, 2025

Capacity and Surge Response Leading Into a State of Readiness

Sustaining pandemic readiness requires investment in workforce, infrastructure, and scalable manufacturing practices.

Declining pandemic readiness is cause for concern; as such, the panelists highlight the importance of maintaining manufacturing capacity, a skilled workforce, and robust health infrastructure. Sustainable practices, including leveraging flu vaccine systems, are recommended for better future preparedness.


Related to this article

The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.